Haemacure Corporation last month disclosed the apparent clinical utility of its fibrin sealant in the prevention of post-surgical adhesion:
Haemacure Corporation (TSX : HAE), a Montreal-based specialty bio-therapeutics company developing high-value human plasma-derived protein products for commercialization, disclosed today the positive results of a second preclinical study conducted on the use of its proprietary lead product candidate, the human fibrin sealant Hemaseel(R)HMN, in preventing the formation of post-surgical adhesions in a bleeding surgical model.
In two preclinical studies, this utility was demonstrated in the statistically significant reduction in the incidence, extent and severity of post-surgical adhesions when Haemacure’s fibrin sealant was compared toÂ Interceed(R) Absorbable Adhesion Barrier (Ethicon) and Seprafilm(R) Adhesion Barrier (Genzyme).
A collegue pointed out to me thatÂ Angiotech’s CoSeal is being investigated by Baxter for its use as both a sealant and adhesion protection product.
The topic of anti-adhesion has been addressed in prior business reports by MedMarket Diligence, including the February 2007 reportÂ and is being addressed in the Report #S175 in process,Â “Worldwide Surgical Sealants, Glues and Wound Closure Market, 2009-2013.”
Quite a counterintuitive idea to take a glue and use it for anti-adhesion, but the data supports it.